DAY 2 - Sunday, October 23
|
|
CORNEA SUBSPECIALTY DAY
CXL may play role in keratitis
Orlando—Emerging data are suggesting that corneal collagen crosslinking (CXL) may have a role in the management of infectious keratitis. However, currently there are more questions than answers about the efficacy and safety of this technique, said A. John Kanellopoulos, MD. » MORE
|
|
Data sustain shift to DALK
Orlando—Deep anterior lamellar keratoplasty (DALK) has important advantages for preserving the endothelium compared with penetrating keratoplasty (PK), but DALK is not without limitations, said Rudy Nuijts, MD. » MORE
|
|
REFRACTIVE SUBSPECIALTY DAY
Building on laser refractive surgery
Orlando—Accumulating data are validating the theoretical advantages of the femtosecond laser for improving the safety and efficacy of cataract surgery, but only time will tell what the role of this new technology will be in clinical practice, said Michael C. Knorz, MD, in a keynote lecture. » MORE |
|
Results support FS laser role
Orlando—Use of a femtosecond laser (IntraLase FS) with its FDA-approved IntraLase Enabled Keratoplasty (IEK) software (both Abbott Medical Optics) shows promise as a safe and effective technique for performing bladeless cataract surgery, said James C. Loden, MD. » MORE
|
|
PEDIATRIC SUBSPECIALTY DAY
Propranolol: In place of steroids?
Orlando—Propranolol, a non-selective beta blocker, is an effective treatment for capillary hemangiomas that might be used in place of steroids. The effectiveness of the drug for capillary hemangiomas was discovered serendipitously, resulting in an “explosion” of interest in this treatment, according to David Plager, MD. » MORE
|
|
Dynamic retinoscopy a useful test
Orlando—Dynamic retinoscopy is an underutilized test in ophthalmology that, according to Burton Kushner, MD, has changed his practice. He uses the test to determine patients’ accommodative ability and status and to predict the development of esotropia. » MORE
|
|
RETINA SUBSPECIALTY DAY
Insert beneficial for DME
Orlando—Implantation of a fluocinolone acetonide intravitreal insert (Iluvien, Alimera Sciences) resulted in gains of three or more lines of visual acuity in a significant number of patients, said Peter Campochiaro, MD. » MORE |
|
Ranibizumab effective for DME
Orlando—The multicenter READ 3 study of ranibizumab (Lucentis, Genentech) for diabetic macular edema (DME) showed that at 6 months the visual acuity increases in the 0.5- and the 2-mg groups were similar. Visual acuity and central retinal thickness changes were maintained to the 1-year evaluation, said Quan Nguyen, MD. » MORE |
|
FROM THE SHOW FLOOR
Addition launches CXL system
Orlando—Addition Technology announced that it will launch a corneal collagen crosslinking (CXL) system (Intacs XL) as an additional treatment option for keratoconus and other ectatic conditions. » MORE |
|
New Heidelberg software released
Orlando—New software (version 5.4) is available for Heidelberg Engineering’s Spectralis product line. » MORE |
DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times. The sponsor does not endorse and is not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.
|
|
|
Exhibit Hall Hours
Saturday, October 22
9 a.m. – 5 p.m.
Sunday, October 23
9 a.m. – 5 p.m.
Monday, October 24
9 a.m. – 5 p.m.
Tuesday, October 25
9 a.m. – 3 p.m.
We welcome your feedback!
Please send your comments to:
Mark Dlugoss
Editor-in-Chief
Advanstar Eye Health Group
[email protected] |
|
